Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Redwood City, California
- Most recent report
- 10-Q, filed Aug 13, 2026
- Incorporated
- Delaware
- Filings on record
- 196 filings
- On EDGAR
- CIK 1770069
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
Financials 4
News 8 of 11
Prospectuses and Registrations 8 of 10
- 424B3 Prospectus supplement for an offering Sep 23, 2026
- S-1/A Registration statement for an offering, amended Sep 18, 2026
- S-1 Registration statement for an offering Sep 9, 2026
- S-8 Registration statement for an employee plan Mar 26, 2026
- 424B3 Prospectus supplement for an offering Oct 27, 2025
- S-8 Registration statement for an employee plan Oct 27, 2025
- FWP Free writing prospectus Oct 27, 2025
- FWP Free writing prospectus Oct 6, 2025
Proxies 2
Ownership 8 of 146
- 4 Insider reported a trade Sep 18, 2026
- 144 Notice of a proposed sale of restricted stock Sep 16, 2026
- SCHEDULE 13G Large holder reported a passive stake Aug 20, 2026
- 4 Insider reported a trade Aug 19, 2026
- 4 Insider reported a trade Aug 19, 2026
- 4 Insider reported a trade Aug 19, 2026
- 4 Insider reported a trade Aug 19, 2026
- 4 Insider reported a trade Aug 19, 2026
Other 8 of 23
- EFFECT Notice that a registration became effective Sep 23, 2026
- ARS Annual report sent to shareholders Apr 29, 2026
- CERT Exchange certified a listing Oct 24, 2025
- 8-A12B Registration of a security for exchange listing Oct 24, 2025
- DRSLTR Aug 22, 2025
- DRS/A Draft registration statement, submitted confidentially, amended Aug 22, 2025
- UPLOAD Comment letter from SEC staff Aug 12, 2025
- DRS/A Draft registration statement, submitted confidentially, amended Jul 30, 2025
Everything here comes from MapLight Therapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.